High‐dose vitamin D to attenuate bone loss in patients with prostate cancer on androgen deprivation therapy: A phase 2 RCT
Luke J. Peppone(University of Rochester Medical Center), Supriya G. Mohile(University of Rochester Medical Center), Jonathan W. Friedberg(University of Rochester), Charles Kamen(University of Rochester), Karen M. Mustian(University of Rochester Medical Center), Charles E. Heckler(University of Rochester Medicine), Jennifer E. Reschke(University of Rochester Medicine), Chunkit Fung(Oslo University Hospital), Michelle C. Janelsins(University of Rochester), Eva Culakova(University of Rochester), Amber S. Kleckner(University of Maryland, Baltimore), J. Edward Puzas(University of Rochester Medical Center), Julia E. Inglis(University of Rochester Medicine)
Cited by 13
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Comparison of Pharmaceutical, Psychological, and Exercise Treatments for Cancer-Related Fatigue
|JAMA Oncology|2017|913
Prevalence, Demographics, and Psychological Associations of Sleep Disruption in Patients With Cancer: University of Rochester Cancer Center–Community Clinical Oncology Program
|Journal of Clinical Oncology|2009|564
Applied Discriminant Analysis
|Technometrics|1995|409